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OBJECTIVES The purpose of this study was to examine the changes in leukocyte mitochondrial
transmembrane potential (MTP) and its association with apoptosis in congestive heart failure
(CHF).
BACKGROUND Congestive heart failure is a heterogeneous syndrome with multiple hemodynamic, neuroen-
docrine and immune abnormalities. Although edematous CHF may be associated with
endotoxemia and increased cytokine production, peripheral blood leukocyte functions in
advanced CHF remain unclear.
METHODS Thirty patients with acute decompensated CHF (mean age [ SEM] 74.9  3.1 years) and
20 healthy controls underwent determination of MTP, intracellular oxidants and apoptosis in
three subsets of peripheral blood leukocytes. The measurements were repeated after the time
of recompensation.
RESULTS Patients with acute CHF showed marked MTP reduction and increased intracellular oxidant
formation in three subsets of leukocytes upon entry into the study. These changes were more
prominent in patients with peripheral edema. The decline in MTP was correlated with the
severity of the peripheral edema and plasma concentration of cortisol, nitrogen metabolites
and tumor necrosis factor-alpha (p  0.01). After clinical stabilization, MTP gradually
recovered. Leukocytes underwent increased propensity of apoptosis one week after the time
of recompensation.
CONCLUSIONS The mitochondrial depolarization and apoptosis of leukocytes in decompensated heart failure
suggest that CHF is associated with severity-dependent impairments in leukocyte function.
Accentuated hormonal and cytokine abnormalities and increased circulating oxidants may
contribute to these changes. Early and aggressive management of advanced heart failure is
helpful in the recovery of these immune abnormalities. (J Am Coll Cardiol 2001;38:
1693–700) © 2001 by the American College of Cardiology
Congestive heart failure (CHF) is associated with altered
immune status and increased oxidative stress (1,2). In-
creased levels of inflammatory cytokines and neopterin have
been demonstrated in edematous or cachectic CHF patients
(3–5). Several recent researches proposed the paradigm that
intestinal bacterial translocation, a phenomenon secondary
to mesenteric venous congestion and intestinal edema, may
induce endotoxemia and lead to immune activation in CHF
patients (6). Of note, CHF is associated with more heter-
ogeneous neuroendocrine and immune disturbances (7,8).
For example, an increased level of blood cortisol, which may
potentially cast deleterious effects on the physiological state
and vitality of leukocytes (9,10), is a part of CHF-associated
metabolic alternations (3). Furthermore, the impairment in
leukocyte oxidative bursts in patients with severe heart
failure seems to further support the “negative facet” of
CHF-related immune disturbances (5).
Cellular energization status is crucial to the activity and
vitality of cells (11). Mitochondrial transmembrane poten-
tial (MTP), the driving force of cellular adenosine triphos-
phate (ATP) formation, is an important determinant of the
energization status and physiological activity of the cell, and
also constitutes an obligate step in cell-death programs
(12–15). A reduction in MTP can be triggered by various
apoptotic inducers such as glucocorticoids, ischemia, reac-
tive oxygen species (16), tumor necrosis factor-alpha
(TNF-) (17) and nitrogen metabolites (18). These induc-
ers may cause functional disturbance in mitochondrial
respiratory chain components or the inappropriate opening
of the permeability transition (PT) pores, resulting in
mitochondrial depolarization and MTP disruption (13).
The mitochondrial functional status of immunocompetent
cells in patients with CHF has not been investigated yet.
Because the extent of neuroendocrine and immune dis-
turbances in CHF patients is correlated with the severity of
heart failure and hemodynamic parameters (2,7,19), it is
tempting to speculate that these abnormalities may be more
prominent at the deterioration stage of CHF. To gain
further insight into the mixed and complex responses of the
immune system to CHF, we conducted a prospective,
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observational study to investigate peripheral blood leukocyte
MTP and its propensity for apoptosis in 30 decompensated
CHF patients. The study subjects were grouped according
to whether peripheral edema existed or not, and were
sequentially gauged to evaluate time-sequence changes after
appropriate management of CHF.
METHODS
Subjects. From October 1999 to October 2000 we pro-
spectively enrolled 40 patients who were admitted to the
intensive care unit of the Taipei Veterans General Hospital
because of acute decompensated CHF. The patients were
recruited within 6 h after onset of their symptoms. The
diagnosis of CHF was based on the presence of dyspnea,
cardiomegaly, and documented left-ventricular dysfunction
(all patients had a left-ventricular ejection fraction measured
by radionuclide ventriculography of 40%). Patients with
premorbid inflammatory or infectious disorders, malig-
nancy, uremia, and decompensated liver disease, and those
taking anti-inflammatory agents, steroid hormones, or an-
tioxidants prior to entering this study, were excluded.
Patients developing cardiogenic shock or those mandating
nitrite therapy during hospitalization were also excluded due
to the possible interference in leukocyte mitochondrial
function (9). Recompensation of CHF was defined as the
disappearance of dyspnea at rest, peripheral edema, hypox-
emia and pulmonary infiltrations in chest radiographs.
Twenty healthy volunteers free of CHF, or any condition
compatible with the excluding criteria listed above, donated
blood samples as reference materials after overnight fasting.
Written informed consent was obtained from all study
participants, and the performance of this study was ap-
proved by the Research Ethics Committee at the Taipei
Veterans General Hospital, Taiwan.
Hemodynamic monitoring. Twenty of the 35 included
patients (8 in the endematous group and 12 in the non-
edematous group) underwent pulmonary artery cannulation
with a balloon-tipped, flow-directed, 7F Swan-Ganz cath-
eter through the internal jugular or subclavian vein. Pressure
waveforms were recorded in the right atrium, pulmonary
trunk and pulmonary artery wedge positions. Cardiac out-
put was determined by applying the thermo-dilution
method.
Blood sampling. Immediately upon fulfillment of the in-
clusion criteria, 10 ml of venous blood was obtained by
venipuncture for sampling. Part of the blood (5 ml) was
anticoagulated with heparin and assayed immediately for
various fluorescence stainings (see subsequent text). The
remaining blood samples were EDTA-anticoagulated, cen-
trifuged and stored in a frozen state at 70°C. Repeated
blood sampling was performed under fasting states at the
time of hemodynamic recompensation (mean duration
5.6  2.4 days after admission) and one week thereafter.
Cell isolation. The heparinized blood was divided into
several 200 l aliquots. Each aliquot was treated with 3 ml
of 1:10 erythrocyte lysing buffer (PharMingen, San Diego,
California) for 10 min. The supernatant was discarded and
the cells were washed with phosphate-buffered saline and
resuspended with Hank’s balanced salt solution (Gibco
BRL, Paisley, Scotland) to approximately 105 cells/ml. The
viability of leukocytes was confirmed to be more than 95%
by trypan blue exclusion.
For assaying DNA fragmentation, polymorphonuclear
leukocytes (PMN) and peripheral blood mononuclear cells
(PBMC) were separated from whole blood by Histopaque-
1119 (Sigma, St. Louis, Missouri) and Ficoll-Hypaque
(Pharmacia, Uppsala, Sweden) centrifugation. After isola-
tion and resuspension, the cells were fixed with 1% para-
formaldehyde and 70% ethanol and stored under70°C for
further assay.
Cell labeling. Aliquots of leukocytes were labeled sepa-
rately with the following fluorescent probes. The MTP was
specified by incorporating the fluorochrome 5,5,6,6-
tetrachloro-1,13,3-tetraethylbenzimidazolcarbocyanine
iodide (JC-1) (Molecular Probes, Eugene, Oregon) in cell
staining. The leukocyte suspension was incubated with 5
mol/l JC-1 for 20 min at 37°C. After staining, JC-1 was
incorporated into the mitochondria, where it either formed
monomers (green fluorescence, 527 nm) or, at high MTP,
aggregates (red fluorescence, 590 nm). The ratio between
fluorescence intensity of JC-1 aggregates and monomers can
reliably reflect MTP (20). In addition, intracellular oxidants
were evaluated by incubating the cells with 20 mol/l
2,7-dichlorofluorescein (DCF) diacetate (Molecular
Probes) for 20 min at 37°C (21).
The DNA fragmentation assay. The DNA fragmentation
of nuclei was assessed using terminal deoxynucleotidyltrans-
ferase to incorporate fluorescein-isothiocyanate-dUTP into
nuclei (TUNEL assay), following the manufacturer’s pro-
tocol (APO-BRDU Kit, PharMingen, San Diego, Califor-
nia) (22). The percentage of apoptosis was calculated as the
number of cells in the high fluorescence intensity population
divided by the total number of cells (PMN or PBMC)
analyzed.
Flow-cytometric evaluation. Fluorescence was analyzed
by cytometry using a FACScan (Becton Dickinson, San
Jose, California) fitted with an air-cooled argon laser emit-
ting at 488 nm. During analysis, a gate was set on the dot
plot of forward and side scatter to include PMN, monocytes
Abbreviations and Acronyms
CHF  congestive heart failure
DCF  2,7-dichlorofluorescein
JC-1  5,5,6,6-tetrachloro-1,13,3-
tetraethylbenzimidazolcarbocyanine iodide
MTP  mitochondrial transmembrane potential
PBMC  peripheral blood mononuclear cells
PMN  polymorphonuclear leukocytes
PT  permeability transition
TNF  tumor necrosis factor
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or lymphocytes. The identity of cell populations in each
analysis was confirmed by counterstaining with CD45 and
CD14 antibody reagents (23). The total number of events
from each sample was made such that at least 5,000 events
were collected for each cell population. To ensure consis-
tency of data among the different measurements, the pho-
tomultiplier values of the detector in FL1 and FL2 re-
mained constant and were set at 450 V throughout all the
experiments. All the analyzing procedures were undertaken
within 3 h after blood sampling.
Associating plasma factors. For the following assays,
EDTA-anticoagulated plasma samples were used. Nitrogen
metabolites, including nitrites and nitrates, were measured
by a modified Griess method (BIOXYTECH Nitric Oxide
Non-Enzymatic Assay, Oxis, Portland, Oregon), with a
detection sensitivity of 1 mol/l. Lipid peroxides (including
malondialdehyde and 4-hydroxyalkenals) were analyzed by a
colorimetric assay kit (LPO assay kit, CalBiochem, San
Diego, California), with a detection limit of 0.1 mol/l.
Cortisol was assayed by a radioimmunoassay (RIA) kit
(DSL-2000 Cortisol RIA kit, Diagnostic Systems, Web-
ster, Texas), with a detection sensitivity of 2.7 nmol/l. Both
TNF- and interleukin-6 (IL-6) concentrations were mea-
sured using ultrasensitive ELISA kits (BioSource, Cama-
rillo, California), with a minimum detectable range of 1.7
pg/ml and 0.7 pg/ml, respectively.
Statistics. All continuous data were expressed as mean 
SEM. Time-sequence changes and group comparisons were
assessed by the Mann-Whitney U test or two-way analysis
of variance (ANOVA) models with repeated-measures
ANOVA methods when appropriate. Spearman rank cor-
relation or Pearson’s product moment correlation analyses
were used to establish the relation between variables. A p
value  0.01 was considered statistically significant.
RESULTS
Of the 40 CHF patients initially recruited, 5 mandating
nitrate therapy were excluded, as well as another 5 who
developed infectious complications or eventually died dur-
ing the hospitalization period. The remaining 30 patients
who achieved recompensation for a mean of 5.3  1.2 days
were included in the final assessments. Among them, 15
presenting with peripheral edema were categorized into the
edematous group, with the remaining 15 categorized into
the nonedematous group. Peripheral edema was graded
according to its severity and range of distribution (0, no
edema; 1, mild; 2, moderate; 3, severe). The clinical char-
acteristics of these patients are shown in Table 1.
Leukocyte MTP. Analysis by flow cytometry revealed a
significant reduction of MTP in PMN, monocytes, and
lymphocytes at the onset of decompensated CHF (Fig. 1,
left panel). The decline of MTP was more prominent in
the edematous than in the nonedematous patients, while
the difference being statistically significant only in lympho-
cytes. After clinical stabilization of CHF, MTP gradually
increased, reaching normal or subnormal levels one week
after recompensation. The sequential changes in MTP in
the three subsets of leukocytes were all statistically signifi-
cant.
Intracellular oxidants. Intracellular oxidants were signifi-
cantly increased in the three subsets of leukocytes upon
patients’ admissions (Fig. 1, right panel). The highest levels
were noted for monocytes. Patients with edematous CHF
exhibited higher DCF fluorescence levels than did those
Table 1. Clinical Characteristics of Patients and Controls
Edematous Nonedematous Control
Number 15 15 20
Age (yrs) 72.6  3.7 78.5  2.8 68.5  1.6
Gender (M/F) 9/7 10/5 18/12
NYHA functional class
Initial 3.0  0.3 3.8  0.0
After treatment 2.3  0.1 2.5  0.1
Cause
Ischemic 7 10
Idiopathic 8 5
Peripheral edema (median grade) 3 0*
LVEF (%) 36.2  5.1 35.3  2.7
CTR (%) 64.7  9.6 68.3  4.8
CI (l/min/m2)† 2.4  0.2 2.2  0.1
PAWP (mm Hg)† 19.4  1.5 22.6  2.0
RAP (mm Hg)† 17.8  1.2 14.4  0.9*
Diuretic agent 15 15
Inotropic agent 12 15
ACE inhibitor or other vasodilators 10 13
*p  0.01, compared between two study groups; †Data obtained from 8 subjects in the edematous group and 12 in the
nonedematous group. Data are presented as mean value  SEM.
ACE  angiotensin-converting enzyme; CHF  congestive heart failure; CI  cardiac index; CTR  cardiothoracic ratio;
LVEF  left ventricular ejection fraction; NYHA  New York Heart Association; PAWP  pulmonary artery wedge pressure;
RAP  right atrial pressure.
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with nonedematous CHF. The DCF fluorescence gradually
declined after recompensation of CHF, but remained
slightly supranormal one week later.
Apoptosis. The DNA fragmentation assay revealed a de-
layed appearance of apoptotic leukocytes in CHF subjects
one week after the time of recompensation (Fig. 2). The
percentage of apoptotic cells was higher in PMN (up to
42.9%) than in PBMC (up to 20.8%). Leukocytes from
patients with edematous CHF showed a higher percentage
of apoptosis than those of nonedematous subjects, but the
difference did not reach statistical significance except that at
one week for PBMC (p  0.01 by Mann-Whitney U test).
Associating plasma factors. Figure 3 displays time-
sequence changes of plasma nitrogen metabolites, lipid
peroxides, cortisol and inflammatory cytokine (TNF- and
IL-6) concentrations during the observation period. Plasma
nitrite/nitrate levels increased approximately two-fold from
admission, as compared with the control value. More
prominent changes were noted in plasma lipid peroxide
levels, with the increase reaching sevenfold compared with
Figure 1. Time-sequence changes of mitochondrial transmembrane potential (MTP) (left panel) and intracellular oxidants (right panel) in peripheral
blood polymorphonuclear leukocytes (PMN), monocytes and lymphocytes. The MTP was expressed as the ratio of the mean fluorescence intensity of
5,5,6,6-tetrachloro-1,13,3-tetraethylbenzimidazolcarbocyanine iodide (JC-1) aggregates and JC-1 monomers. Intracellular oxidants were expressed as
the mean fluorescent intensity of 2,7-dichlorofluorescein (DCF). *p  0.01 compared among different time points; †p  0.01 compared between two
congestive heart failure (CHF) groups.
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the control value. The increases in plasma oxidants were
more pronounced in the edematous subjects. Plasma cortisol
levels increased significantly from admission in the edema-
tous CHF subjects, and the levels normalized one week after
the time of recompensation. Finally, plasma TNF- and IL-6
levels markedly increased in patients with edematous CHF,
and remained supranormal throughout the study period.
Correlations of MTP with clinical indexes. The levels of
MTP on admission are variably correlated with clinical and
laboratory markers (Table 2). When the patients were
considered collectively, MTP levels declined with increased
severity of peripheral edema and higher right atrial pressure
(p  0.01). In contrast, MTP levels did not correlate
significantly with indexes of left ventricular function. The
MTP was inversely related with most plasma markers, with
the correlations reaching statistical significance in nitrogen
metabolites, cortisol and TNF- (p  0.01).
DISCUSSION
The major findings of this study provide evidence showing
that impaired leukocyte mitochondria functional status and
an increased propensity for apoptotic death may constitute
an important part of immune disturbances in CHF patients.
Mitochrondria depolarization occurred in three subsets of
peripheral leukocytes and was more prominent in patients
with peripheral edema. The mitochondrial dysfunction
gradually recovered after clinical stabilization. These find-
ings suggest that CHF is associated with severity-dependent
immune dysfunctions that are partly recoverable with ap-
propriate management.
Possible mechanisms underlying MTP disruption. Sev-
eral factors may potentially contribute to the leukocyte
MTP disruption in patients with CHF. First, increased
intracellular oxidants, as evidenced by increased DCF fluo-
rescence, may lead to oxidation of carrier molecules in the
respiratory chain and/or mitochondria pyridine nucleotides,
which either hamper the respiratory coupling or induce
mitochondrial PT (16) with resultant MTP disruption.
Second, increased DCF fluorescence might also signify
greater production of mitochondrial reactive nitrogen spe-
cies such as nitric oxide or peroxynitrite (21), which is able
to cause reversible or irreversible inhibition of respiratory
enzymes and lead to MTP disruption (24–26). Alterna-
tively, increased plasma nitrogen metabolites, probably sec-
ondary to endothelial nitric oxide synthase activation by
endotoxemia and increased circulating cytokine in edema-
tous CHF (27,28), may also trigger MTP disruption in
leukocytes (9). Third, plasma TNF-, with the potential to
deplete cells of nicotinamide adenosine diphosphate (NAD)
and adenosine triphosphate (ATP) due to the activation of
poly-ADP-ribose polymerase (29), is another culprit in
mitochondrial depolarization. Although it was unclear
whether the plasma concentration of TNF- in our CHF
patients was adequate to elicit these changes, the fact that
leukocytes from patients with CHF have both enhanced
expression of surface TNF- receptors and more respon-
siveness to TNF- (30) seems to heighten this possibility.
Finally, cortisol also seems to be a potential contributor of
MTP disruption (31,32). The plasma concentration of
cortisol increased to about 500 nmol/l in our CHF patients,
exceeding concentrations that were able to induce lympho-
cyte MTP disruption and apoptosis in vitro (33).
Disruption and apoptosis of MTP. Recent evidence pro-
posed the paradigm that the reduction in MTP may
constitute an early and committed step in cell apoptosis
(14,15). The dissipation in MTP may induce apoptotic
programs by disturbing mitochondrial ATP production and
by inducing the release of mitochondrial matrix solutes,
cytochrome C, and other pro-apoptotic factors (34). In the
present study, a significant percentage (23.5%) of peripheral
blood PMN underwent apoptosis at the decompensated
stage of CHF. Intriguingly, the propensity of PMN apo-
ptosis increased for a period after the time of recompensa-
tion. Also, PBMC underwent apoptosis at this stage. It
seems that these phenomena may reflect the temporal effect
of downstream events in the apoptotic program induced by
mitochondrial depolarization.
Comparisons between edematous and nonedematous
CHF. The increased plasma concentrations of TNF-
and IL-6 in CHF patients, especially those with periph-
eral edema, corroborate previous findings (1). The in-
Figure 2. Propensity of apoptosis in polymorphonuclear leukocytes (PMN)
(A) and peripheral blood mononuclear cells (PBMC) (B) as determined by
flow cytometric TUNEL assay. The percentage of cells with DNA
fragmentation of nuclei equals the high fluorescein isothiocyanate-dUTP–
labeled population divided by the total cell population. *p 0.01 compared
among different points. A significant (p  0.01) interaction exists between
time variable and group variable in (B).
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crease in inflammatory cytokines may potentially augment
phagocytic oxidant production and lead to more intravas-
cular oxidants, as shown by Keith et al. (2) and our study
(Fig. 3B). Our study further demonstrates a two-fold
increase in plasma nitrogen metabolites and a 1.5-fold
increase in plasma cortisol in the edematous CHF patients.
Because all these factors have the potential to induce
mitochondrial depolarization and apoptosis, the greater
degree of their abnormalities seems to account for the more
prominent leukocyte dysfunctions in the edematous CHF
patients. The significant correlation of MTP levels with the
severity of peripheral edema renders further support to this
notion.
Possible clinical implications. The CHF-related immune
alterations seem to be multifold and remain to be clarified.
Congestive heart failure with peripheral edema or cachexia
has been shown to be associated with immune activation
and increased circulating pro-inflammatory cytokines
(1,35). Conversely, reduced host defenses, as evidenced by
an increased susceptibility to pneumonia, have also been
reported in CHF patients (36). The present study further
explores the pathomechanisms underlying the immune dis-
turbances associated with CHF by demonstrating an im-
paired leukocyte mitochondria functional status and an
increased propensity for apoptosis in severe and untreated
heart failure. These phenomena may constitute a pivotal
Figure 3. Time sequence changes of plasma nitrogen metabolites (A), lipid peroxides (B), cortisol (C), tumor necrosis factor (TNF)- (D) and interleukin-6
(E) concentrations. *p 0.01 compared among different time points; †p 0.01 compared between two congestive heart failure (CHF) groups. A significant
(p  0.01) interaction exists between time variable and group variable in (E).
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facet of immune dysfunction in advanced CHF. That
leukocyte dysfunction partly improved after the restoration
of hemodynamic functions may underscore the importance
of early and aggressive management of advanced heart
failure.
Study limitations. Unlike well-controlled laboratory inves-
tigations where a single variable can be manipulated at a
time, circulating leukocytes are under simultaneous influ-
ence by a number of contributing factors, making a definite
conclusion very difficult to reach. In addition, medications
used in the treatments of CHF, such as catecholamines, also
have the potential to induce lymphocyte apoptosis (37), thus
making the interpretation of this study’s results more
complex. Cautions must also be taken in the interpretation
of the results of the TUNEL assay, as it may be too sensitive
to detect not only the specific DNA fragmentations in
apoptosis, but also the nicks in DNA that were produced by
topoisomerase (38) or the random DNA degradation oc-
curring during necrosis (39,40). Further in-depth studies are
demanded to verify the different pathways that are involved
in the immune abnormalities associated with acute CHF.
Conclusions. Congestive heart failure is a state of physio-
logical stress. The stress resides not only in the level of
cardiovascular function, but also at the cell level, as exem-
plified by leukocyte mitochondrial depolarization and apo-
ptosis. The impaired functional status of peripheral blood
leukocytes may impair host defenses in the acute deteriora-
tion stage of CHF. Successful management of CHF not
only improves the patient’s hemodynamic status but also
restores the leukocyte energization status. These findings
may shed new light on both the pathogenesis and the
treatment of immune disturbances in CHF.
Reprint requests and correspondence: Dr. Kelvin Tsai, Oxida-
tive Stress Clinical Research Group and Division of Critical Care,
Department of Medicine, Taipei Veterans General Hospital, 2F,
201, Section 2, Shih-Pai Rd., Taipei, 112, Taiwan. E-mail:
kctsai@vghtpe.gov.tw.
REFERENCES
1. Niebauer J, Volk H, Kemp M, et al. Endotoxin and immune activation
in chronic heart failure: a prospective cohort study. Lancet 1999;353:
1838–42.
2. Keith M, Geranmayegan A, Sole MJ, et al. Increased oxidative stress
in patients with congestive heart failure. J Am Coll Cardiol 1998;31:
1352–6.
3. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor- and
tumor necrosis factor receptors in the failing human heart. Circulation
1996;93:704–11.
4. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and
catabolic/anabolic imbalance in chronic heart failure and their impor-
tance for cardiac cachexia. Circulation 1997;96:526–34.
5. Wiedermann CJ, Beimpold H, Herold M, et al. Increased levels of
serum neopterin and decreased production of neutrophils superoxide
anions in chronic heart failure with elevated levels of tumor necrosis
factor-alpha. J Am Coll Cardiol 1993;22:1897–901.
6. Anker SD, Egerer KR, Volk H, et al. Elevated soluble CD14 receptors
and altered cytokines in chronic heart failure. Am J Cardiol 1997;79:
1426–30.
7. Lommi J, Kupari M, Koskinen P, et al. Blood ketone bodies in
congestive heart failure. J Am Coll Cardiol 1996;28:665–72.
8. Anker SD, Coats AJ. Cardiac cachexia: a syndrome with impaired
survival and immune and neuroendocrine activation. Chest 1999;115:
836–47.
9. Hortelano S, Dallaporta B, Zamzami N, et al. Nitric oxide induces
apoptosis via triggering mitochondrial permeability transition. FEBS
Lett 1997;410:373–7.
10. Brunetti M, Martelli N, Colasante A, Piantelli M, Musiani P, Aiello
FB. Spontaneous and glucocorticoid-induced apoptosis in human
mature T lymphocytes. Blood 1995;86:4199–205.
11. Boobis AR, Fawthrop DJ, Davies DS. Mechanisms of cell toxicity.
Curr Opin Cell Biol 1990;2:231–7.
12. Richter C, Schweizer M, Cossarizza A, Franceschi C. Control of
apoptosis by the cellular ATP level. FEBS Lett 1996;378:107–10.
13. Crompton M. The mitochondrial permeability transition pore and its
role in cell death. Biochem J 1999;341:233–49.
14. Petit PX, Susin SA, Zamzami N, Mignotte B, Kroemer G. Mito-
chondria and programmed cell death, back to the future. FEBS Lett
1996;396:7–13.
15. Marchetti P, Hirsch T, Zamzami N, et al. Mitochondrial permeability
transition triggers lymphocyte apoptosis. J Immunol 1996;157:
4830–6.
16. Chernyak BV, Bernardi P. The mitochondrial permeability transition
pore is modulated by oxidative agents through both pyridine nucleo-
tides and glutathione at two separate sites. Eur J Biochem 1996;238:
623–30.
17. Kroemer G, Zamzami N, Susin SA. Mitochondrial control of apo-
ptosis. Immunol Today 1997;18:44–51.
Table 2. Correlations of Leukocyte Mitochondrial Transmembrane Potential With Clinical
Markers of Congestive Heart Failure
PMN
MTP
Monocyte
MTP
Lymphocyte
MTP
NYHA functional class† 0.279 0.052 0.136
LVEF‡ 0.361 0.255 0.412
Edema† 0.468* 0.418 0.503*
CI‡ 0.241 0.432 0.104
PAWP‡ 0.033 0.158 0.097
RAP‡ 0.464* 0.417 0.478*
Lipid peroxides‡ 0.397 0.395 0.342
Nitrogen metabolites‡ 0.451* 0.315 0.597*
Cortisol‡ 0.472* 0.394 0.431
TNF-‡ 0.464* 0.302 0.358
Interleukin-6‡ 0.277 0.244 0.455
*p  0.01; †Spearman rank correlation coefficient; ‡Pearson’s product moment correlation coefficient.
CI  cardiac index; LVEF  left ventricular ejection fraction; MTP  mitochondrial transmembrane potential; NYHA 
New York Heart Association; PAWP pulmonary artery wedge pressure; PMN polymorphonuclear cells; RAP right atrial
pressure; TNF  tumor necrosis factor.
1699JACC Vol. 38, No. 6, 2001 Kong et al.
November 15, 2001:1693–700 Leukocyte Mitochondrial Depolarization and Apoptosis in CHF
18. Hortelano S, Dallaporta B, Zamzami N, et al. Nitric oxide induces
apoptosis via triggering mitochondrial permeability transition. FEBS
Lett 1997;410:373–7.
19. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated
circulating levels of tumor necrosis factor in severe chronic heart
failure. N Engl J Med 1990;323:236–41.
20. Cossarizza A, Ceccarelli D, Masini A. Functional heterogeneity of an
isolated mitochondrial population revealed by cytofluorometric analy-
sis at the single organelle level. Exp Cell Res 1996;222:84–94.
21. Hempel SL, Buettner GR, O’Malley YQ, Wessels DA, Flaherty DM.
Dihydrofluorescein diacetate is superior for detecting intracellular
oxidants: comparison with 2,7-dichlorodihydrofluorescein diacetate,
5(and 6)-carboxy-27-dichlorodihydrofluorescein diacetate, and dihy-
drorhodamine 123. Free Radic Biol Med 1999;27:146–59.
22. Li X, Traganos F, Melamed MR, Darzynkiewicz Z. Single-step
procedure for labeling DNA strand breaks with fluorescein- or
BODIPY-conjugated deoxynucleotides. Detection of apoptosis and
bromodeoxyuridine incorporation. Cytometry 1995;20:172–80.
23. Qwens MA, Loken MW. Components of flow cytometric immuno-
phenotyping. In: Owens MA, Loken MR, editors. Flow Cytometry
Principles for Clinical Laboratory Practice. New York, NY: Wiley-
Liss, 1995:17–44.
24. Wallerath T, Gath I, Aulitzky WE, Pollock JS, Kleinert H, Forster-
mann U. Identification of the NO synthase isoforms expressed in
human neutrophils, granulocytes, megakaryocytes and platelets.
Thromb Haemostasis 1997;77:163–7.
25. Fortenberry JD, Owens ML, Brown LA. S-nitrosoglutathione en-
hances neutrophil DNA fragmentation and cell death. Am J Physiol
1999;276:L435–42.
26. Brown GC. Nitric oxide and mitochondrial respiration. Biochim
Biophys Acta 1999;1411:351–69.
27. Lefer AM. Endotoxin, cytokines, and nitric oxide in shock. Shock
1994;1:79–80.
28. Rockey DC, Chung JJ. Regulation of inducible nitric oxide synthase in
hepatic sinusoidal endothelial cells. Am J Physiol 1996;271:G260–7.
29. Agarwal S, Drysdale BE, Shin HS. Tumor necrosis factor-mediated
cytotoxicity involves ADP-ribosylation. J Immunol 1988;140:4187–
92.
30. Nozaki N, Yamaguchi S, Yamaoka M, Okuyama M, Nakamura H,
Tomoike H. Enhanced expression and shedding of tumor necrosis
factor (TNF) receptors from mononuclear leukocytes in human heart
failure. J Mol Cell Cardiol 1998;30:2003–12.
31. Distelhorst CW. Glucocorticoid-induced apoptosis. In: Kaufmann
SH, editor. Apoptosis. San Diego, CA: Academic Press, 1997:247–70.
32. Zamzami N, Marchetti P, Castedo M, et al. Sequential reduction of
mitochondrial transmembrane potential and generation of reactive
oxygen species in early programmed cell death. J Exp Med 1995;182:
367–77.
33. Brunetti M, Martelli N, Colasante A, Piantelli M, Musiani P, Aiello
FB. Spontaneous and glucocorticoid-induced apoptosis in human
mature T lymphocytes. Blood 1995;86:4199–205.
34. Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization
of mitochondrial apoptosis-inducing factor. Nature 1999;397:441–6.
35. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated
circulating levels of tumor necrosis factor in severe chronic heart
failure. N Engl J Med 1990;323:236–41.
36. Farr BM, Woodhead MA, Macfarlane JT, et al. Risk factors of
community-acquired pneumonia diagnosed by general practitioners in
the community. Respir Med 2000;94:422–7.
37. Cioca DP, Watanabe N, Isobe M. Apoptosis of peripheral blood
lymphocytes is induced by catecholamines. Jpn Heart J 2000;41:385–
98.
38. Froelich-Ammon SJ, Osheroff N. Topoisomerase poisons: harnessing
the dark side of enzyme mechanism. J Biol Chem 1995;270:21429–32.
39. Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H, Bukowska K,
Bursch W, Schulte-Hermann R. In situ detection of fragmented DNA
(TUNEL assay) fails to discriminate among apoptosis, necrosis, and
autolytic cell death: a cautionary note. Hepatology 1995;21:1465–8.
40. Charriaut-Marlangue C, Ben-Ari Y. A cautionary note on the use of
the TUNEL stain to determine apoptosis. Neuroreport 1995;7:61–4.
1700 Kong et al. JACC Vol. 38, No. 6, 2001
Leukocyte Mitochondrial Depolarization and Apoptosis in CHF November 15, 2001:1693–700
